Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

BI-D1870

🥰Excellent
Catalog No. T6171Cas No. 501437-28-1

BI-D1870 is a highly specific, blood-brain-permeable, and ATP-competitive inhibitor of the N-terminal AGC kinase domain of RSK, with IC50 values ​​of 31 nM, 24 nM, 18 nM, and 15 nM for RSK1, RSK2, RSK3, and RSK4.

BI-D1870

BI-D1870

🥰Excellent
Purity: 99.43%
Catalog No. T6171Cas No. 501437-28-1
BI-D1870 is a highly specific, blood-brain-permeable, and ATP-competitive inhibitor of the N-terminal AGC kinase domain of RSK, with IC50 values ​​of 31 nM, 24 nM, 18 nM, and 15 nM for RSK1, RSK2, RSK3, and RSK4.
Pack SizePriceAvailabilityQuantity
1 mg$48In Stock
2 mg$71In Stock
5 mg$139In Stock
10 mg$217In Stock
25 mg$353In Stock
50 mg$497In Stock
100 mg$693In Stock
500 mg$1,450In Stock
1 mL x 10 mM (in DMSO)$119In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "BI-D1870"

Select Batch
Purity:99.43%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
BI-D1870 is a highly specific, blood-brain-permeable, and ATP-competitive inhibitor of the N-terminal AGC kinase domain of RSK, with IC50 values ​​of 31 nM, 24 nM, 18 nM, and 15 nM for RSK1, RSK2, RSK3, and RSK4.
Targets&IC50
RSK3:18 nM (cell free), RSK2:24 nM (cell free), RSK1:31 nM (cell free), RSK4:15 nM (cell free)
In vitro
METHODS: HEK-293 cells were incubated with BI-D1870 (10 μM, 15 min, 4 h total) To examine whether BI-D1870 could inhibit RSK activity in cells, the effect of BI-D1870 on RSK-catalyzed phosphorylation of its known substrates in HEK-293 cells was investigated using PMA as an agonist to activate ERK1/ERK2 and RSK isoforms.
RESULTS Incubation of cells with BI-D1870 significantly inhibited PMA-induced phosphorylation of GSK3α and GSK3β. In contrast, BI-D1870 had little effect on PMA-induced activation of ERK1/ERK2 (catalyzed by Raf and MKK1) or phosphorylation of CREB at Ser at any time point. [1]
METHODS: Oral cancer cell lines (SCC2095, SCC4, SCC9, Ca922 and HSC-3) and NHOK cells were treated with BI-D1870 (1, 2, 3, 4, 5.28 or 48 hours), and the growth of these cells was detected by MTT.
RESULTS BI-D1870 showed a dose-responsive antiproliferative effect on OSCC cells. [3]
METHODS: Cells transfected with immunofluorescent GFP-LC3 were treated with BI-D1870 (0.5, 2 μM) for 48 hours and observed under a confocal microscope; DAPI staining was used to locate the nucleus, and Western blot of LC3B was observed in cells treated with BI-D1870 for 48 hours.
RESULTS BI-D1870 induced autophagy, and Western blot of LC3B-II showed that this induction was dose-dependent. [3]
In vivo
METHODS: Two days after immunization with MOG peptide, BI-D1870 (0.5 mg/kg) was injected intraperitoneally into mice and repeated every other day for 11 days.
RESULTS Mice showed delayed neurological deficits; BI-D1870 treatment had a moderate protective effect against weight loss. [4]
Kinase Assay
Purified His6–RSK1, His6–RSK2 or GST–RSK21–389:S381E (1–2 units/ml) were assayed for 10 min at 30 °C in a 50 μl assay mixture in Buffer A containing 30 μM substrate peptide (KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK), 10 mM magnesium acetate and 100 μM of [γ-32P]ATP. Reactions were terminated and analyzed as described previously. The amount of enzyme that catalyzed the phosphorylation of 1 nmol of substrate peptide in 1 min was termed one unit. In order to assay RSK and MSK1 in HEK-293 or Rat-2 cell lysates, these kinases were immunoprecipitated from the cell lysates (0.1 mg of lysate protein for RSK and 0.3 mg for MSK1) and assayed as described previously, except that for RSK assays the immunoprecipitates were washed twice with Buffer A containing 1 mM ATP and twice with Buffer A prior to the assay, as a precaution to ensure dissociation of BI-D1870 from the RSK isoforms [1].
Cell Research
The rat embryo fibroblast cell line, Rat-2 cells were cultured on 10 cm-diameter dishes in Dulbecco's Modified Eagle's medium supplemented with 10% (v/v) FBS. HEK-293 cells were cultured on 10 cm-diameter dishes in Dulbecco's Modified Eagle's medium supplemented with 10% FBS and 1×antimycotic/antibiotic solution. Prior to stimulation, cells were cultured in the absence of serum for 16 h. Inhibitors were dissolved in DMSO at a 1000-fold higher concentration than they were used at. These inhibitors, or the equivalent volume of DMSO as a control, were added to the tissue culture medium 30 min prior to stimulation unless indicated otherwise. The final concentration of DMSO in the culture medium was 0.1% and had no effect on agonist-induced activation or phosphorylation of any of the substrates examined. The cells were stimulated with the indicated agonists and lysed in 1 ml of ice-cold Lysis Buffer and centrifuged at 16000 g at 4 °C for 5 min. The supernatants were frozen in liquid nitrogen and stored at ?80 °C until use. Protein concentrations were determined using the Bradford method with BSA as the standard [1].
Animal Research
Myelin oligodendrocyte glycoprotein (MOG) peptide 35–55. (MEVGWYRSPFSRVVHLYRNGK) (BEX) was used to induce EAE in C57/BL6J mice. Mice were injecteds.c. with 200 g of MOG peptide in100 L of PBS emulsified in 100 L complete Freund's adjuvant (CFA) that was further supplemented with five mg mL?1 Mycobacterium tuberculosis (H37Ra). In addition, 500 ng pertussis toxin was injected i.p. on days zero and two. The RSK inhibitor (BI-D1870; 0.5 mg kg?1) was injected i.p. into mice two days after immunization with MOG peptide, and injection was repeated every other day for 11 days. Mice that received only dimethyl sulfoxide (DMSO) solution were used as controls. Paralysis was evaluated according to the following scale: zero, no disease; one, tail limpness; two, hind limb weakness; three, hind limb paralysis; four, forelimb weakness; five, quadriplegia; six, death. For histological analysis, CNS samples were fixed with 4% paraformaldehyde and sliced at 4 m, and then hematoxylin & eosin (H & E) staining was performed [4].
Chemical Properties
Molecular Weight391.42
FormulaC19H23F2N5O2
Cas No.501437-28-1
SmilesCC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12
Relative Density.1.297
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 6.88 mg/mL (17.56 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 7.2 mg/mL (18.39 mM), suspension.In vivo: Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
Solution Preparation Table

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy BI-D1870 | purchase BI-D1870 | BI-D1870 cost | order BI-D1870 | BI-D1870 chemical structure | BI-D1870 in vivo | BI-D1870 in vitro | BI-D1870 formula | BI-D1870 molecular weight